DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including Advanced Cervical Cancer clinical trials and nonclinical stage products. It also covers the Advanced Cervical Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Advanced Cervical Cancer Treatment Landscape
To explore more information on the latest breakthroughs in the Advanced Cervical Cancer Pipeline treatment landscape of the report, click here @ Advanced Cervical Cancer Pipeline Outlook
Advanced Cervical Cancer Overview
Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can’t usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones.
Key Takeaways from the Advanced Cervical Cancer Pipeline Report
Request a sample and discover the recent advances in Advanced Cervical Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Cervical Cancer Treatment Landscape
Advanced Cervical Cancer Emerging Drugs Profile
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.
Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.
Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company’s most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.
Advanced Cervical Cancer Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Advanced Cervical Cancer. The companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
For further information, refer to the detailed Advanced Cervical Cancer Unmet Needs, Advanced Cervical Cancer Market Drivers, and Market Barriers, click here for Advanced Cervical Cancer Ongoing Clinical Trial Analysis
Scope of the Advanced Cervical Cancer Pipeline Report
Dive deep into rich insights for drugs for Advanced Cervical Cancer Market Drivers and Advanced Cervical Cancer Market Barriers, click here @ Advanced Cervical Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Advanced Cervical Cancer Mergers and acquisitions, Advanced Cervical Cancer licensing activities @ Advanced Cervical Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services